The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults with transthyretin amyloid cardiomyopathy, or ATTR-CM.
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
Attruby (acoramidis) is a small molecule approved to treat adults with transthyretin amyloid cardiomyopathy. It will have a ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...
The U.S. FDA has approved Attruby, a new drug by BridgeBio, for treating a rare heart condition, redefining a market led by ...
Medical Xpress on MSN11d
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosisA new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback